US 12,109,213 B2
Fused heterotricyclic organic compounds, pharmaceutical compositions, and medical uses thereof
Tim Kamerzell, Overland Park, KS (US)
Assigned to Alevere Medical Corporation, Broomfield, CO (US)
Filed by Alevere Medical Corporation, Broomfield, CO (US)
Filed on Jul. 6, 2022, as Appl. No. 17/858,712.
Application 17/126,126 is a division of application No. 16/048,603, filed on Jul. 30, 2018, granted, now 10,888,563, issued on Jan. 12, 2021.
Application 16/048,603 is a division of application No. 15/133,533, filed on Apr. 20, 2016, granted, now 10,058,553, issued on Aug. 28, 2018.
Application 17/858,712 is a continuation of application No. 17/126,126, filed on Dec. 18, 2020, granted, now 11,382,916.
Application 15/133,533 is a continuation of application No. PCT/US2014/061517, filed on Oct. 21, 2014.
Claims priority of provisional application 61/893,564, filed on Oct. 21, 2013.
Claims priority of provisional application 61/893,544, filed on Oct. 21, 2013.
Claims priority of provisional application 61/893,529, filed on Oct. 21, 2013.
Claims priority of provisional application 61/893,556, filed on Oct. 21, 2013.
Prior Publication US 2022/0378795 A1, Dec. 1, 2022
Int. Cl. A61K 31/4985 (2006.01); A61K 8/49 (2006.01); A61K 9/00 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/53 (2006.01); A61Q 19/00 (2006.01); A61Q 19/06 (2006.01); A61K 31/4162 (2006.01); C07D 487/14 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 8/4946 (2013.01); A61K 8/4953 (2013.01); A61K 8/4966 (2013.01); A61K 9/0019 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/53 (2013.01); A61Q 19/00 (2013.01); A61Q 19/06 (2013.01); A61K 31/4162 (2013.01); C07D 487/14 (2013.01)] 19 Claims
 
1. A cosmetic method of modifying the contour of a subject's externally exposed body part containing fat, the method comprising administering to said body part an amount of a compound of Formula I effective to modify the contour of said body part, wherein Formula I is represented by:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is phenyl, 5-6 membered heteroaryl, aralkyl, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —(C1-C6)alkylene-OH, or —(C1-C6)alkylene-O—(C1-C6)alkyl, wherein said phenyl, 5-6 membered heteroaryl, aralkyl, and cycloalkyl are optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, hydroxyl, —(C1-C6)alkoxy, and —N(R5)R6;
R2 and R3 each represent independently for each occurrence hydrogen, —(C1-C6)alkyl, or halogen;
R4 is —C(O)N(R5)R6, —N(R5)C(O)R6, —CO2R6, —C(O)R6, —(C1-C6)alkylene-N(R5)R6, —(C1-C6)alkylene-OR6, or —(C1-C6)alkoxy;
R5 and R6 each represent independently for each occurrence hydrogen, —(C1-C6)alkyl, or —(C3-C6)cycloalkyl; or when R5 and R6 are attached to the same nitrogen atom, then R5 and R6 may be taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocycle; and
n and m each represent independently 1 or 2.